ICCM IceCure Medical Ltd.

BEARISH Impact: 5/10 6-K
Horizon immediate Filed Jun 2, 2026 Processed 12d 19h ago SEC 0001213900-26-063815
Notable filing: 6-K
Latest settled — T+1d
ICCM ▲ +9.21% at T+1d
SHORT call ✗ call lost -9.21% · α vs SPY -9.90% · entry $4.17 → $4.55
Next anchor: T+5d due 6d ago
Last close $2.39 (close Jun 12) · +42.69% from $4.17 entry (call sign-flipped)
Entry anchored
Jun 2, 08:40 AM ET
via Databento tick
T+1d
+9.21%
call -9.21% · α -9.90%
$4.55
settled 12d ago
T+5d
call — · α —
due 6d ago
T+20d
call — · α —
in 16d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

IceCure Medical announced a 1-for-30 reverse share split effective June 4, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split reduces outstanding shares from ~84.2M to ~2.8M but does not change fundamental value, serving as a technical measure to avoid delisting. Combined with recent equity raises and a history of poor stock performance, the action signals ongoing financial distress.

Actionable Insight

The reverse split is a technical fix to maintain listing, not a catalyst for recovery. Given the company's pre-revenue status, repeated dilution, and negative historical stock performance, further capital raises or adverse clinical/regulatory news could drive additional downside. Monitor for compliance status and any financing announcements post-split.

Key Facts

  • 1-for-30 reverse share split approved by board, effective June 4, 2026.
  • Outstanding shares reduce from 84,201,034 to approximately 2,806,701.
  • Purpose is to meet Nasdaq $1.00 minimum bid price; cure deadline is November 9, 2026.
  • Company has a small market cap of ~$16M and pre-revenue status.
  • Prior 424B5 equity offer for $4.34M filed 21 days ago, signaling ongoing cash needs.

Financial Impact

No direct financial impact; reverse split does not affect cash or operations.

Risk Factors

  • Potential failure to maintain Nasdaq compliance if stock price falls again after split.
  • Ongoing cash burn may require additional dilutive financing.
  • Reverse splits often signal distress and can lead to further selling pressure.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
88% bullish (8 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-063815
Document: ea029311601ex99-1.htm0001213900-26-063815
Document: 0001213900-26-063815-index-headers.html0001213900-26-063815
Document: 0001213900-26-063815-index.html0001213900-26-063815
Document: 0001213900-26-063815.txt0001213900-26-063815
9 reports for ICCM
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+20▲ +41.80%May 6, 2026
Filters
Rows
Reports for ICCM — sortable, filterable
Type Now
Jun 2, 2026
12d ago
6-K
BEARISH ★ 5/10
$4.17 $4.55▼ −9.21%▼ −9.90%$2.39 (+42.69%)
May 12, 2026
4w ago
424B5
BEARISH ★ 7/10
$0.2370 $0.2370· 0.00%▼ −0.00%$2.39 (−908.44%)
May 12, 2026
4w ago
6-K
MIXED ★ 5/10
$0.2400 $0.2370▼ −1.25%▼ −1.83%$2.39 (+895.83%)
May 6, 2026
5w ago
6-K
BEARISH ★ 7/10
$7.50 $7.20▲ +4.00%▲ +4.83%$2.39 (+68.13%)
Apr 21, 2026
7w ago
6-K
BULLISH ★ 7/10
$0.3500 $0.3570▲ +2.00%▲ +0.98%$2.39 (+582.86%)
Apr 13, 2026
9w ago
EFFECT
NEUTRAL ★ 5/10
$0.3370 $0.3550▲ +5.34%▲ +4.13%$2.39 (+609.20%)
Apr 1, 2026
10w ago
F-1
NEUTRAL ★ 4/10
$0.3000 $0.3020▲ +0.67%▲ +0.19%$2.39 (+696.67%)
Mar 25, 2026
11w ago
EFFECT
NEUTRAL ★ 4/10
$0.5880 $0.3900▼ −33.67%▼ −31.90%$2.39 (+306.46%)
Mar 24, 2026
11w ago
EFFECT
NEUTRAL ★ 5/10
$0.6090 $0.5880▼ −3.45%▼ −4.01%$2.39 (+292.45%)
Showing 9 of 9

US Market Status

Market Closed — Opens in 5h

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access